GlassScriptPhysician profile
Ira H Lavoe
NPI 1730126533
$3,142.54
in general payments reported to CMS, 2019-2025
30 companies · $559 in 2025
The $559 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $264 · 2021: $191 · 2022: $475 · 2023: $530 · 2024: $685 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $498.02 | 2019-2024 | Jornay Pm |
| Corium, LLC | $438.59 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $286.38 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Kaleo, INC. | $239.75 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $207.20 | 2019-2024 | |
| Sanofi Pasteur INC. | $176.35 | 2020-2025 | |
| Collegium Pharmaceutical, INC. | $171.55 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $138.37 | 2021-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $132.84 | 2023-2025 | |
| Tris Pharma INC | $117.62 | 2019-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $98.07 | 2020-2024 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $79.17 | 2019-2021 | |
| Alk-Abello, INC | $74.46 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $65.56 | 2021-2025 | |
| Hologic Sales and Service, LLC | $59.82 | 2023-2024 | Aptima, Affirm Prone Biopsy System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $50.22 | 2021-2022 | |
| Seqirus USA INC | $45.56 | 2025 | Flucelvax |
| Adlon Therapeutics L.P. | $35.44 | 2020 | |
| Kyowa Kirin, INC. | $34.74 | 2023 | Crysvita |
| Supernus Pharmaceuticals, INC. | $24.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.41 | 2019 | |
| Biomarin Pharmaceutical INC. | $20.66 | 2024 | Voxzogo 1.2mg |
| Biomerieux INC | $19.65 | 2025 | |
| Neurelis, INC. | $17.81 | 2025 | Valtoco |
| Sobi, INC | $16.61 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.44 | 2019 | |
| Mission Pharmacal Company | $14.40 | 2019 | |
| Aytu Biopharma, INC. | $14.09 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.83 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Lavoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.